ERBB2 and breast cancer: Although this meta-analysis suggests that IT trastuzumab and HER-2 targeted therapy do not offer obvious advantages as an alternative route of administration, IT therapy can quickly alleviate patients’ neurological symptoms, and many clinical trials have shown that it has considerable efficacy and good tolerability for HER-2-positive breast cancer LMD patients.